Condition: Breast Cancer Female · Breast Reconstruction · Sponsor: DOF Inc.
The goal of this observational study is to evaluate the safety of Acellular Dermal Matrix(ADM) processed by CO2 supercritical fluid technology against other acellular dermal matrix products from different companies that have been washed with detergents in patients undergoing breast reconstruction surgery with implants due to the breast cancer.
This description comes directly from the study's public registry record.
kiyong Hong, Ph.D · +82 02-2072-0310 · kyhong@snu.ac.kr
Hyejin Ryu · +82-10-3514-6968 · rtyuok2@outlook.kr
Always discuss trial participation with your own doctor first.
| Seoul National University Hospital | Seoul, Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06555614